Drug & intervention

sunitinib

RxCUI 357977

Clinical trials35
Recruiting1
Related conditions20
Synonyms1

RxNorm ingredient and formulation relationships

Source-verified product relationships. Every strength, delivery form and RxCUI remains a separate clinical concept.

Loading RxNorm relationships…
Background context

Sunitinib

Sunitinib, sold under the brand name Sutent, is an anti-cancer medication. It is a small-molecule, multi-targeted receptor tyrosine kinase (RTK) inhibitor that was approved by the FDA for the treatment of renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST) in January 2006. Sunitinib was the first cancer drug simultaneously approved for two different indications. As of August 2021, sunitinib is available as a generic medicine in the US.

Read on Wikipedia ↗ Wikidata Q417542 ↗
Background only. Canonical identity remains RxNorm; clinical-trial relationships come from ClinicalTrials.gov.

Clinical trials

35 shown
Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid TumorsNCT05024214 · 2021-11-15
RECRUITING
OPTI - DOSE: Optimal Dosing of Oral Anticancer Drugs in Older AdultsNCT05949424 · 2024-05-01
UNKNOWN
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME TrialNCT03878524 · 2020-04-01
TERMINATED
Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302)NCT03260894 · 2017-12-07
COMPLETED
Sunitinib Treatment on Tissue Sodium Accumulation (TSS2)NCT04368546 · 2015-11-01
COMPLETED
Sunitinib in Never-Smokers With Lung AdenocarcinomaNCT01829217 · 2013-05-01
COMPLETED
Docetaxel With or Without Low-dose, Short Course Sunitinib in Refractory Solid TumorsNCT01803503 · 2013-05-01
UNKNOWN
Cytochrom p450 3A4 and 1A2 Phenotyping for the Individualization of Treatment With Sunitinib or Erlotinib in Cancer PatientsNCT01402089 · 2012-01-01
COMPLETED
Maximal Androgen Depletion Followed by Randomization of Maximal Androgen Ablation With Molecular Targeted TherapiesNCT01254864 · 2011-03-16
COMPLETED
Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic MalignanciesNCT01306045 · 2011-02-08
COMPLETED
Resection of Pulmonary Metastasis in Clear Cell Renal Cell Carcinoma +/-Adjuvant Sunitinib Therapy (SMAT)NCT01216371 · 2010-10-01
TERMINATED
Neoadjuvant Sunitinib With Paclitaxel/Carboplatin in Patients With Triple-Negative Breast CancerNCT00887575 · 2009-06-01
COMPLETED
Brain Mets - Capecitabine Plus Sunitinib and WBRTNCT00570908 · 2009-02-01
TERMINATED
Multimodality Phase II Study in Prostate CancerNCT00734851 · 2008-12-01
TERMINATED
Sunitinib Plus Prednisone In Patients With Metastatic Castration-Resistant Prostate Cancer After Failure Of Docetaxel ChemotherapyNCT00676650 · 2008-07-01
TERMINATED
Irinotecan, Carboplatin, and Sunitinib in First Line Extensive-Stage Small Cell Lung CancerNCT00695292 · 2008-06-01
COMPLETED
Study Of Sunitinib With Capecitabine In Breast CancerNCT00662025 · 2008-04-01
COMPLETED
An Open-label Phase II Study With SUTENT in Patients Suffering From Hormone Refractory Prostate CancerNCT00748358 · 2008-03-01
COMPLETED
Sunitinib as a Second-line Treatment for Patients With Recurrent Small Cell Lung CancerNCT00620347 · 2008-03-01
COMPLETED
Sunitinib Maintenance Therapy After Induction Platinum-Based Chemotherapy in Patients With ES-SCLCNCT00616109 · 2007-09-01
COMPLETED
Efficacy And Safety Of Sunitinib In Women With Advanced Breast CancerNCT00471276 · 2007-08-01
COMPLETED
A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.NCT00428220 · 2007-07-01
COMPLETED
A Study In Patients With Non-Small Cell Lung Cancer To Test If Erlotinib Plus SU011248 Is Better Than Erlotinib AloneNCT00457392 · 2007-07-01
COMPLETED
A Study of Sunitinib in Combination With Bevacizumab, Carboplatin, and Paclitaxel in Patients With Advanced Non-Small Cell Lung Cancer (SABRE-L)NCT00434226 · 2007-03-01
TERMINATED
Study Tests The Safety And Effectiveness Of SU011248 In Patients With Non-Small Cell Lung Cancer Having Brain MetastasesNCT00372775 · 2007-03-01
COMPLETED
Phase II Sunitinib Prog Met AIPCNCT00599313 · 2007-03-01
COMPLETED
A Study of Sunitinib in Combination With Bevacizumab and Paclitaxel in Previously Untreated Patients With Metastatic Breast Cancer (SABRE-B)NCT00434356 · 2007-03-01
TERMINATED
Phase II Trial of Sunitinib in BAC or Never-Smokers With Any Lung AdenocarcinomaNCT00430261 · 2007-01-01
COMPLETED
Study Of SU011248 In Combination With Docetaxel And Trastuzumab In Patients With Advanced Breast Cancer HER-2 PositiveNCT00372424 · 2006-12-01
COMPLETED
A Study Of SU011248 Plus Paclitaxel Versus Bevacizumab Plus Paclitaxel In Patients With Advanced Breast CancerNCT00373256 · 2006-11-01
COMPLETED
A Study In Patients With Non-Small Cell Lung Cancer Testing If Erlotinib Plus SU011248 (Sunitinib) Is Better Than Erlotinib AloneNCT00265317 · 2006-06-01
COMPLETED
Study of SU11248 in Men With Advanced Prostate CancerNCT00299741 · 2006-03-01
COMPLETED
A Study Of SU011248 As Therapy In Patients With Locally Advanced Or Metastatic Non-Small Cell Lung CancerNCT00113516 · 2005-09-01
COMPLETED
Study Of SU011248 In Patients With Metastatic Non-Small Cell Lung CancerNCT00092001 · 2005-01-01
COMPLETED
Study Of SU011248 In Combination With Docetaxel In Patients With Advanced CancerNCT00712504 · 2004-07-01
COMPLETED

Conditions being studied

Non-Small Cell Lung Cancer6Breast Cancer4Prostate Cancer4Carcinoma, Non-Small-Cell Lung3Lung Cancer3Renal Cell Carcinoma3Breast Neoplasms2Hepatocellular Carcinoma2Metastatic Breast Cancer2Prostatic Neoplasms2Solid Tumors2Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive1Adenocarcinoma1Advanced Breast Cancer1Advanced Gastric Cancer1Advanced Solid Tumors1Advanced/Metastatic Breast Cancer1Advanced/Metastatic Non-Small Cell Lung Cancer1Anatomic Stage IV Breast Cancer AJCC v81Anemia1

Drug identity and terminology: RxNorm. Trial relationships: ClinicalTrials.gov.